Heron Therapeutics, Inc. (NASDAQ:HRTX – Free Report) – Equities researchers at Northland Capmk boosted their FY2023 earnings per share (EPS) estimates for shares of Heron Therapeutics in a note issued to investors on Wednesday, November 15th. Northland Capmk analyst C. Byrnes now expects that the biotechnology company will earn ($0.82) per share for the year, up from their prior estimate of ($0.95). The consensus estimate for Heron Therapeutics’ current full-year earnings is ($1.09) per share. Northland Capmk also issued estimates for Heron Therapeutics’ Q4 2023 earnings at ($0.14) EPS.
Other equities analysts have also issued reports about the company. StockNews.com raised Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday. Needham & Company LLC decreased their price target on Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a research note on Wednesday.
Heron Therapeutics Price Performance
Shares of HRTX stock opened at $1.09 on Friday. Heron Therapeutics has a 12-month low of $0.50 and a 12-month high of $3.41. The firm has a market capitalization of $163.58 million, a price-to-earnings ratio of -1.14 and a beta of 1.12. The business has a 50 day simple moving average of $0.86 and a 200 day simple moving average of $1.26.
Insider Buying and Selling
In related news, CFO Ira Duarte bought 85,000 shares of the business’s stock in a transaction on Thursday, November 16th. The shares were bought at an average cost of $0.89 per share, for a total transaction of $75,650.00. Following the completion of the acquisition, the chief financial officer now directly owns 85,000 shares in the company, valued at $75,650. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. In other Heron Therapeutics news, CFO Ira Duarte purchased 85,000 shares of the stock in a transaction dated Thursday, November 16th. The shares were bought at an average cost of $0.89 per share, with a total value of $75,650.00. Following the completion of the transaction, the chief financial officer now owns 85,000 shares in the company, valued at approximately $75,650. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Craig A. Collard purchased 150,000 shares of the stock in a transaction dated Thursday, November 16th. The stock was acquired at an average cost of $0.92 per share, for a total transaction of $138,000.00. Following the completion of the transaction, the chief executive officer now owns 186,496 shares of the company’s stock, valued at approximately $171,576.32. The disclosure for this purchase can be found here. 6.40% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Heron Therapeutics
A number of institutional investors have recently added to or reduced their stakes in the company. Tejara Capital Ltd lifted its stake in Heron Therapeutics by 28.6% during the third quarter. Tejara Capital Ltd now owns 2,109,681 shares of the biotechnology company’s stock worth $2,173,000 after purchasing an additional 469,548 shares during the period. Rubric Capital Management LP lifted its stake in Heron Therapeutics by 127.3% during the third quarter. Rubric Capital Management LP now owns 26,713,503 shares of the biotechnology company’s stock worth $27,515,000 after purchasing an additional 14,963,503 shares during the period. Adage Capital Partners GP L.L.C. raised its stake in shares of Heron Therapeutics by 100.0% in the third quarter. Adage Capital Partners GP L.L.C. now owns 2,000,000 shares of the biotechnology company’s stock valued at $2,060,000 after acquiring an additional 1,000,000 shares during the last quarter. Northern Trust Corp raised its stake in shares of Heron Therapeutics by 12.6% in the third quarter. Northern Trust Corp now owns 1,022,605 shares of the biotechnology company’s stock valued at $1,053,000 after acquiring an additional 114,032 shares during the last quarter. Finally, JW Asset Management LLC raised its stake in shares of Heron Therapeutics by 9.1% in the third quarter. JW Asset Management LLC now owns 2,407,418 shares of the biotechnology company’s stock valued at $2,480,000 after acquiring an additional 200,000 shares during the last quarter. 81.77% of the stock is owned by institutional investors and hedge funds.
About Heron Therapeutics
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
- Five stocks we like better than Heron Therapeutics
- How to Invest in Music Stocks
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- How to invest in marijuana stocks in 7 steps
- MarketBeat Week in Review – 11/13 – 11/17
- Investing In Preferred Stock vs. Common Stock
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.